On January 7, 2025 Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, reported a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target (Press release, Alloy Therapeutics, JAN 7, 2025, View Source [SID1234649453]). In return, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5 million. Alloy will also be eligible to receive discovery, development, and commercial milestone payments of over $400 million, as well as tiered royalties on sales of any products resulting from the collaboration. This collaboration underscores a shared commitment to advancing innovative therapeutics in the CNS space.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Alloy’s AntiClastic Antisense platform allows drug developers to realize the true potential of antisense therapeutics by reaching intracellular disease targets at the RNA level. The platform addresses limitations of current antisense chemistries relating to therapeutic index. This technology platform was launched by Alloy in 2023 after exclusively licensing its underlying intellectual property which implements a novel spatial conformation of the oligonucleotide developed by Sudhir Agrawal of Arnay Sciences.
"At Alloy Therapeutics, we’re transforming RNA therapeutics by bridging foundational insights with modern innovation," said Vinod Vathipadiekal, Chief Scientific Officer, Genetic Medicines at Alloy Therapeutics. "Our work on the AntiClastic Antisense platform and the data generated is pushing the technology beyond current standards and driving innovation that has the potential to redefine what’s possible in RNA therapeutics. With the capabilities we have built and validated, we are excited to work with Sanofi, and we look forward to continuing to deliver on Alloy’s commitment to open collaboration and accessible technologies to ensure these breakthroughs can drive the development of superior RNA-based therapies for patients."
Through the collaboration, Sanofi will leverage their neuroscience expertise and collaborate with Alloy to use the AntiClastic Antisense platform for delivery of therapeutics to the brain, aiming to develop a novel class of genetic medicine capable of crossing the blood-brain barrier.
"We’re excited to partner with Sanofi, a global leader in healthcare innovation, on this landmark licensing agreement for our AntiClastic Antisense platform," said Errik Anderson, Alloy Therapeutics CEO and Founder. "When we began working with Dr. Agrawal, a renowned leader in antisense therapeutics, to integrate his groundbreaking work into Alloy’s genetic medicines platform, we were confident in its potential to revolutionize antisense drug development and reshape the broader drug discovery landscape. This collaboration exemplifies Alloy’s adaptable, multi-modality approach, providing our partners with a comprehensive suite of discovery solutions and access to novel platforms to accelerate the development of the most effective therapies for patients in need."